ASH 2021 – Jennifer A. Woyach
Jennifer A. Woyach explains which factors need to be considered when choosing the frontline regimen for patients with early-stage CLL, how resistance to BTK inhibition can be tackled in later lines, if chemoimmunotherapy still has a role in the treatment of CLL and highlights the most interesting findings on the management of treatment-naïve CLL patients.
Here is the full ASH 2021 report.
More posts
Promising novel approaches in various B-cell malignancies
Promising novel approaches in various B-cell malignancies POLARIX: polatuzumab
Phase II data on novel BTK inhibitors for patients with Waldenström’s macroglobulinemia
Phase II data on novel BTK inhibitors for patients with Waldenström’s macroglobulin
Marginal zone lymphoma: PI3Kδ inhibition and beyond
Marginal zone lymphoma: PI3Kδ inhibition and beyond CITADEL-204: parsaclisib in
Mantle cell lymphoma: refining clinical outcomes beyond the current boundaries
Mantle cell lymphoma: refining clinical outcomes beyond the current boundaries
Management of patients with relapsed/refractory CLL: what is new?
Management of patients with relapsed/refractory CLL: what is new? VISION: stop-
Determining first-line CLL/SLL treatment strategies with optimized efficacy and safety
Determining first-line CLL/SLL treatment strategies with optimized efficacy and saf
